189 related articles for article (PubMed ID: 24806110)
1. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY; Campion L; Ansquer C; Frampas E; Mathieu C; Robin P; Bournaud C; Vuillez JP; Taieb D; Rousseau C; Drui D; Mirallié E; Borson-Chazot F; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1501-10. PubMed ID: 24806110
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
Kraeber-Bodéré F; Salaun PY; Ansquer C; Drui D; Mirallié E; Faivre-Chauvet A; Barbet J; Goldenberg DM; Chatal JF
Tumour Biol; 2012 Jun; 33(3):601-6. PubMed ID: 22396039
[TBL] [Abstract][Full Text] [Related]
5. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
6. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
7. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Chatal JF; Campion L; Kraeber-Bodéré F; Bardet S; Vuillez JP; Charbonnel B; Rohmer V; Chang CH; Sharkey RM; Goldenberg DM; Barbet J;
J Clin Oncol; 2006 Apr; 24(11):1705-11. PubMed ID: 16549819
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of
Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
10.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
12. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.
Treglia G; Villani MF; Giordano A; Rufini V
Endocrine; 2012 Dec; 42(3):535-45. PubMed ID: 22527889
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
15. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.
Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D
Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
